Reliq Health Technologies, Inc. Announces New Contract with US Nephrology Clinic to Provide iUGO Care to Chronic Kidney Disease Patients

Rhea-AI Summary

Reliq Health Technologies Inc. (OTC:RQHTF) announced a new contract with a US Nephrology practice to utilize its iUGO Care platform for monitoring Chronic Kidney Disease (CKD) patients. With over 36 million Americans affected by CKD, the platform aims to help manage medication compliance and co-morbidities like diabetes and hypertension. Reliq expects to onboard 5,000 patients by year-end, generating average revenue of $65 per patient per month. This marks a significant step in expanding its virtual care solutions within the healthcare market.

Positive

• New contract with a Nephrology practice for CKD patient monitoring.
• Projected onboarding of 5,000 patients by year-end.
• Expected average revenue of $65/month per patient, enhancing revenue stream.

Negative

• None.

HAMILTON, Ontario, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed a new contract with a US Nephrology practice to use Reliq’s proprietary iUGO Care platform to monitor Chronic Kidney Disease (CKD) patients.

“It is a testament to the flexibility of our platform that it can be used to manage so many different complex chronic conditions,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “We are pleased to be working with our newest client, a Nephrology Practice in Texas, to monitor Chronic Kidney Disease patients and help improve their health outcomes. Over 36 Million Americans have CKD and the majority of these patients also have either diabetes and/or hypertension, the two primary risk factors for developing Chronic Kidney Disease. Using our highly scalable iUGO Care platform, Nephrologists can help monitor medication compliance and manage patients’ co-morbidities like diabetes and high blood pressure, helping to reduce or prevent further damage to the kidneys that could lead to End Stage Renal Disease (ESRD) and the need for costly and disruptive interventions like dialysis or a kidney transplant. We will begin onboarding patients next week, and expect to have at least 5,000 kidney disease patients on the platform by the end of this calendar year, at an average revenue of $65 USD/patient/month.”

Reliq Health
Reliq Health Technologies is a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.

ON BEHALF OF THE BOARD

“Dr. Lisa Crossley”

CEO and Director

For further information please contact:

Company Contact
Investor Relations at ir@reliqhealth.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the "Company") does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.

FAQ

What contract did Reliq Health Technologies announce on February 24, 2021?

Reliq Health announced a contract with a US Nephrology practice to use its iUGO Care platform for monitoring Chronic Kidney Disease patients.

How many patients does Reliq expect to onboard by the end of 2021?

Reliq expects to onboard at least 5,000 kidney disease patients by the end of the year.

What is the average expected revenue per patient for Reliq's iUGO Care platform?

The average expected revenue is $65 USD per patient per month.

What chronic conditions does Reliq's iUGO Care platform manage?

The platform manages Chronic Kidney Disease, diabetes, and hypertension among other complex chronic conditions.